Evident, formerly a wholly owned subsidiary of Olympus Corporation, announced its fifth annual Image of the Year competition is now open for entries through April 30, 2024.
This article highlights the superiority of Microfluidic Modulation Spectroscopy (MMS) over Circular Dichroism (CD) in detecting and characterizing structural changes in beta-sheet-rich proteins.
This article highlights RedShiftBio's MMS™ technology, detailing its effectiveness in proteintherapeutic analysis through enhanced sensitivity and dynamic range.